These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29740896)

  • 1. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
    Rebordosa C; Plana E; Aguado J; Thomas S; García-Gil E; Perez-Gutthann S; Castellsague J
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):126-133. PubMed ID: 29740896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013.
    Raluy-Callado M; Lambrelli D; MacLachlan S; Khalid JM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():925-37. PubMed ID: 25999708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity.
    Mapel DW; Dalal AA; Johnson PT; Becker LK; Hunter AG
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1477-86. PubMed ID: 26251587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK.
    Rothnie KJ; Numbere B; Gelwicks S; Lu Y; Sharma R; Compton C; Ismaila AS; Quint JK
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2673-2685. PubMed ID: 38022832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of using the new GOLD classification on the distribution of COPD severity in clinical practice.
    Hernández M; García G; Falco J; García AR; Martín V; Ibarrola M; Quadrelli S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():351-356. PubMed ID: 29403272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GOLD Classification of COPD: Discordance in Criteria for Symptoms and Exacerbation Risk Assessment.
    Mittal R; Chhabra SK
    COPD; 2017 Feb; 14(1):1-6. PubMed ID: 27723367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients.
    Kawamatawong T; Onnipa J; Suwatanapongched T
    Int J Chron Obstruct Pulmon Dis; 2018; 13():761-769. PubMed ID: 29535516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The distribution of COPD in UK general practice using the new GOLD classification.
    Haughney J; Gruffydd-Jones K; Roberts J; Lee AJ; Hardwell A; McGarvey L
    Eur Respir J; 2014 Apr; 43(4):993-1002. PubMed ID: 24176990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review.
    Czira A; Purushotham S; Iheanacho I; Rothnie KJ; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():719-731. PubMed ID: 37151760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study.
    Cabrera C; Casanova C; Martín Y; Mirabal V; Sánchez Mdel C; Álvarez F; Juliá G; Cabrera-Navarro P; García-Bello MÁ; Marín JM; de-Torres JP; Divo M; Celli B
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1217-22. PubMed ID: 27354780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peak expiratory flow rate as a surrogate for forced expiratory volume in 1 second in COPD severity classification in Thailand.
    Pothirat C; Chaiwong W; Phetsuk N; Liwsrisakun C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1213-8. PubMed ID: 26150713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations.
    Jones PW; Nadeau G; Small M; Adamek L
    Respir Med; 2014 Jan; 108(1):129-35. PubMed ID: 24041746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity.
    Chen CZ; Ou CY; Wang WL; Lee CH; Lin CC; Chang HY; Hsiue TR
    COPD; 2012 Jun; 9(3):276-80. PubMed ID: 22360379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse relationship between nonadherence to original GOLD treatment guidelines and exacerbations of COPD.
    Foda HD; Brehm A; Goldsteen K; Edelman NH
    Int J Chron Obstruct Pulmon Dis; 2017; 12():209-214. PubMed ID: 28123293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a claims-based prediction model for COPD severity.
    Macaulay D; Sun SX; Sorg RA; Yan SY; De G; Wu EQ; Simonelli PF
    Respir Med; 2013 Oct; 107(10):1568-77. PubMed ID: 23806285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
    Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
    Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.